BTN3A1

Biosion to Present Three Posters at the 2024 AACR Meeting

Retrieved on: 
星期四, 三月 21, 2024
HER2, Malignancy, CD16, Trastuzumab, Head, B cell, Cancer, Patient, BTN3A3, IND, AACR, BTN3A1, Cholangiocarcinoma, CD40, NK, Vaccine

"We are thrilled to present three posters at the AACR annual meeting.

Key Points: 
  • "We are thrilled to present three posters at the AACR annual meeting.
  • BSI-111 binds specifically to CD16a without recognizing CD16b and binds the two allelic variants of CD16A - 158F and 158V with similar high affinity.
  • Additionally, Biosion's partner, CTTQ Pharma, OBI Pharma and Pyxis Oncology, will also be presenting posters at the AACR meeting.
  • In 2019, Biosion licensed Greater China rights of BSI-038 to CTTQ and retains all rights for development and commercialization in the rest of the world.

Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
星期四, 三月 16, 2023
Poster, Cancer, AACR, FC, CD20, Patient, Autoimmune disease, Fragment crystallizable region, Primate, BTN3A1, Cytokine release syndrome, Toxicity, Vaccine

AUSTIN, TX and DURHAM, NC, March 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, from the company’s GADLEN platform.

Key Points: 
  • “We are pleased to share pre-clinical data demonstrating that the CD20-targeted GADLEN efficiently directs small numbers of human Vγ9Vδ2 T cells to serially kill greater than 99% of human B cells in a humanized mouse model,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.
  • “These data led to the first study of a GADLEN compound in non-human primates, where once again treatment with a CD20-targeted GADLEN directed low frequencies of endogenous Vγ9Vδ2 T cells to eliminate CD20 positive B cells with a rapid kinetic.
  • Additional meeting information can be found on the AACR website, https://www.aacr.org .
  • The poster will be available under Posters on the Company’s website shortly after the event

Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
星期一, 十一月 7, 2022
Disclosure, Company, FC, GLOBE, Cell, BTN3A1, CD20, Poster, Immunotherapy, Autoimmune disease, Lymphoma, NASDAQ, CD47, Antigen, Society, Regulation, Patient, Cancer, B7-H3, Regulation Fair Disclosure, Vaccine, CD40

AUSTIN, TX and DURHAM, NC, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced preclinical data from the company’s novel GADLEN platform at the 2022 SITC Annual Meeting.

Key Points: 
  • B7-H3 is an antigen that is broadly expressed by many solid tumors, with limited expression in normal tissues.
  • In our preclinical models, our B7-H3 GADLEN directed human gamma delta T cells to selectively kill B7-H3 expressing human tumor cells, including those that expressed very low density of the B7-H3 antigen.
  • Similarly, in our preclinical models, our CD20 GADLEN directed human gamma delta T cells to selectively kill both CD20 expressing tumor cells, and also CD20 expressing healthy B cells.
  • Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer.

Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
星期五, 四月 8, 2022
Cytokine, FC, CD20, NASDAQ, Lymphoma, CD47, Mouse, AACR, Poster, American Association, TGF beta signaling pathway, Cancer, PD-1, Autoimmune disease, ARC, TNF, Association, HVEM, TIGIT, PVR, CD19, GLOBE, Myelocyte, Primate, BTN3A1, Patient, Vaccine, Medical imaging, CD40

AUSTIN, TX and DURHAM, NC, April 08, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced preclinical data at the 2022 American Association for Cancer Research (AACR) Annual Meeting. This includes data from SL-9258 (TIGIT-Fc-LIGHT), derived from the company’s ARC® platform, and the company’s GADLEN platform.

Key Points: 
  • AUSTIN, TX and DURHAM, NC, April 08, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced preclinical data at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
  • This includes data from SL-9258 (TIGIT-Fc-LIGHT), derived from the companys ARC platform, and the companys GADLEN platform.
  • We have made excellent progress advancing compounds in our preclinical pipeline, said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.
  • Together, these results suggest that TIGIT-Fc-LIGHT may provide clinical benefit to patients that are refractory to conventional checkpoint blockade therapy.